跳至主要内容
临床试验/NCT01398839
NCT01398839终止3 期

Safety Study of the VEGA UV-A System to Treat Ectasia

Topcon Medical Systems, Inc.12 个研究点 分布在 1 个国家目标入组 103 人开始时间: 2010年12月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
3 期
状态
终止
入组人数
103
试验地点
12
主要终点
Changes in Corneal Curvature

研究概览

简要总结

The purpose of this research study is to test the safety, tolerability, and effectiveness of corneal collagen cross-linking (CXL) when used to treat ectasia.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • 18 Years of age or older
  • Diagnosis of Ectasia
  • Presence of central or inferior steepening
  • Topography consistent with ectasia
  • BSCVA 20/20 or worse
  • If contact lens wearer; removal of contact lenses for required period of time
  • Signed informed consent
  • Willingness and ability to comply with schedule for follow-up visits

排除标准

  • Previous ocular condition that may predispose the eye for future complications or prevent the possibility of improved vision
  • History of chemical injury or delayed epithelial healing
  • A known sensitivity to study medications
  • Nystagmus or any other condition that would prevent a steady gaze during the treatment or other diagnostic tests
  • A condition that would interfere with or prolong epithelial healing
  • Presence or history of any other condition or finding that makes the patient unsuitable for treatment

研究组 & 干预措施

Sham Control

Sham Comparator

干预措施: Riboflavin (Drug)

CXL Treatment

Experimental

干预措施: VEGA UV-A Illumination System (Device)

CXL Treatment

Experimental

干预措施: Riboflavin (Drug)

结局指标

主要结局

Changes in Corneal Curvature

时间窗: 6 Months

次要结局

未报告次要终点

研究者

申办方类型
Industry
责任方
Sponsor

研究点 (12)

Loading locations...

相似试验